Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.
Are you refining and optimizing your in vivo gene editing delivery strategies for the next generation of gene editors to unlock increased therapeutic efficacy, safety, and cost effectiveness?
Recent clinical trial successes from the likes of Editas Medicine and Tessera Therapeutics have highlighted the importance of targeted delivery for the safety and efficacy of in vivo gene editing. Formulation and delivery experts are uniting to evaluate and optimize cutting edge delivery strategies including LNPs, AAVs, exosomes, peptide shuttles, and polymer nanoparticles at the Gene Editing Delivery Summit. Leverage this insight to supercharge precise and efficient extra-hepatic in vivo gene editing to patients with previously untreatable genetic diseases.
Take advantage of the end-to-end content from discovery, optimization, evaluation, and scale-up topics covered in 2 hands-on workshops and 2 full days of data-driven case studies and discussion sessions from trailblazing drug developers such as Prime Medicine, Beam Therapeutics, Editas Medicine, and AstraZeneca to guide your in vivo gene editing delivery strategies for regulatory approval.
15+
data driven case studies
2
deep diving workshops
7+
hours of networking
18
expert speakers
Expert Speakers
Wes Salomon
Director of Delivery Biology
Tessera Therapeutics
Delai Chen
Director of Nanoparticle Formulation
Beam Therapeutics
Sourav Choudhury
Head of AAV Technologies
Sanofi Genomic Medicines Unit
Anna (Xue) Cheng
Director of R&D Pulmonary Delivery
Feldan Therapeutics
John Zuris
Director of Gene Editing Technologies
Editas Medicine
Marine Hatit
Senior Scientist I – LNP Discovery Lead
Prime Medicine
A Snapshot of Attending Organizations
